Want to see RLAY full AI Analyst Report?
RLAY Stock Chart & Stats
$20.57
-$0.65(-3.40%)
At close: 4:00 PM EDT
$20.57
-$0.65(-3.40%)
Day’s Range― - ―
52-Week Range$5.95 - $21.27
Previous Close$18.19
Volume2.04M
Average Volume (3M)3.08M
Market Cap
$3.98B
Enterprise Value$2.92B
Total Cash (Recent Filing)$910.93M
Total Debt (Recent Filing)$30.66M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 11, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding219,141,630
10 Day Avg. Volume2,263,844
30 Day Avg. Volume3,077,559
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.56
Price to Sales (P/S)94.54
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue281.65
Enterprise Value/Gross Profit-49.71
Enterprise Value/Ebitda-10.27
Forecast
1Y Price Target
$27.14Price Target Upside31.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.6
Revenue Forecast (FY)$11.16M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage gives Relay greater financial flexibility than heavily indebted biotechnology peers and limits near-term interest and refinancing pressure. This supports continued investment in clinical programs and preserves options to raise capital or pursue partnerships as development milestones approach.
Clinical Pipeline ProgressEncouraging Phase 2 zovegalisib data provides evidence that Relay is advancing beyond discovery into meaningful clinical validation. Continued progress in a clinical-stage oncology program can improve partnering prospects, support future milestone opportunities, and strengthen the company’s development platform.
Computational Drug Discovery PlatformRelay’s computational and structure-based approach creates a focused framework for discovering precision oncology medicines and advancing multiple candidates. The combination of structural biology methods, internal programs, and partnered development can support repeatable pipeline generation beyond any single clinical asset.
Bears Say
Deep And Persistent LossesLarge ongoing losses and negative gross profit show that Relay has not yet established a scalable commercial model. Continued operating deficits can consume capital before products generate meaningful revenue, increase dependence on financing, and make future earnings highly dependent on successful clinical execution.
Heavy Cash BurnCash outflows of roughly $263 million over the trailing period indicate that development activities require substantial external funding. Even with an improved burn rate, materially negative free cash flow limits financial independence and increases the importance of financing access, milestones, or partnerships.
Ongoing Equity Dilution RiskExpanding the ATM facility improves access to capital but also creates a durable dilution risk while losses and cash burn persist. Additional share issuance can reduce existing ownership stakes and may become a recurring funding mechanism if internal cash generation remains distant.
Relay Therapeutics News
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $5.95 and its highest was $21.27 in the past 12 months.
What is Relay Therapeutics’s market cap?
Relay Therapeutics’s market cap is $3.98B.
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 18 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.019.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 219,141,630 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 0.101%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Currently, no hedge funds are holding shares in RLAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relay Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.14 (31.95% Upside)
$27.14 (31.95% Upside)
Blogger Sentiment
Neutral
RLAY Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $116.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
168.93%
12-Months-Change
Fundamentals
Return on Equity
-42.27%
Trailing 12-Months
Asset Growth
32.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Relay Therapeutics
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
RLAY Stock 12 Month Forecast
Average Price Target
$27.14
▲(31.95% Upside)
Technical Analysis
IDEAYA Biosciences
―
Tango Therapeutics
―
Edgewise Therapeutics
―
Monte Rosa Therapeutics
―
Erasca
―
Ownership Overview
11.52% Insiders
11.21% Mutual Funds
0.88% Other Institutional Investors
61.00% Public Companies and Individual Investors